The U.S. Food and Drug Administration (FDA) has approved a new drug, daraxonrasib, for the most common form of pancreatic cancer. This landmark approval offers U.S. patients a more effective treatment option against this deadly disease. The daily pill, sold as Rasonque by Revolution Medicines, targets a mutated protein that fuels tumour growth.
Patients taking daraxonrasib nearly doubled their survival time in a clinical study. They lived for a median of 13.2 months compared to 6.7 months for those receiving chemotherapy. This significant improvement came with fewer severe side effects. The drug specifically blocks a mutated protein found in over 90% of pancreatic cancer cases, an approach that eluded drugmakers for decades.
This development represents a crucial step forward in cancer treatment globally. Pancreatic cancer is notoriously difficult to detect early, often spreading before diagnosis. The American Cancer Society estimates about 67,000 new cases will be diagnosed in the United States this year. More than 52,000 people will die from the disease, highlighting the urgent need for better treatments. The five-year overall survival rate for pancreatic cancer is currently only 13%.
Dr. Pashtoon Kasi of City of Hope Orange County, a California-based cancer centre, commented on the drug. He stated, "This is not a cure, it’s one more option for these patients." Dr. Kasi added, "But it’s the best option we’ve ever had." This expert perspective underscores the drug's importance despite not being a complete cure.
The FDA granted expedited approval, acting more than six months ahead of its target date. This swift action reflects the urgent need for new therapies for pancreatic cancer. Kyle Diamantas, the FDA’s acting commissioner, emphasized the agency's commitment. He said, "It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible." This rapid approval process highlights the drug's potential impact.
Unlike other cancers that have seen various chemotherapy alternatives, pancreatic cancer has been particularly challenging. The new drug targets mutations in the RAS gene family, which normally regulates cell growth. Specifically, KRAS mutations are critical in fueling pancreatic cancer. Previously, the structure of these mutated proteins made them seem "undruggable."
Doctors treating pancreatic cancer hope this drug will open doors for more new options. Many experimental drugs are currently in development. Dr. Kasi believes this breakthrough will encourage further research. He noted, "I think this has opened doors for many other companies." He expects more trials to explore this approach in other tumour types. Revolution Medicines is also studying its technology for other cancers, including lung cancer.